Table of Contents
Antibiotic Development Strategies to Understand and Label Microbial Endpoints such as Slow killing, resistance and Failure, AUIC Dosing and Success via Synergy
Introduction
PK/PD: AUIC and Selected Resistance
PK/PD trials of Antibiotics
PPT Slide
MRSA: Issues With Appropriately Dosed Vancomycin?
Comparison of Vancomycin days to eradication for MRSA Infections
Study Design Issues
Strategies for MRSA failing vancomycin after 5 days Tx
PPT Slide
In Vivo Synergy: Quinupristin/Dalfopristin Plus Vancomycin Against MLSBC Strains of MRSA for Endocarditis*
Vancomycin Failure Study
Outcomes
14 Day (% Culture Positive)
PPT Slide
PK/PD
Micro Cure as a Surrogate?
PPT Slide
Clinical Trials are Designed to Assure Equivalence....
ABX Equivalence vs Superiority
Delta, power and sample size on a dichotomous vs continuous endpoint
Alternative View from the Front
Recommendations
Disclosures - J.J. Schentag
|
Author: Jerome J Schentag
|